Brief: Surface Oncology Says Co Entered Into An Exclusive Product License Agreement With Vaccinex, Inc.
03/05/2021 13:23
May 3 (Reuters) - Surface Oncology Inc SURF.O :
* SURFACE ONCOLOGY INC - ON MARCH 23, ENTERED INTO AN
EXCLUSIVE
PRODUCT LICENSE AGREEMENT WITH VACCINEX, INC.
* SURFACE ONCOLOGY - VACCINEX GRANTED CO A WORLDWIDE,
EXCLUSIVE,
SUBLICENSABLE LICENSE COVERING ANTIBODY SRF114 TARGETING CCR8
* SURFACE ONCOLOGY INC - CO PAID VACCINEX A ONE-TIME FEE OF
$850,000
* SURFACE ONCOLOGY INC - VACCINEX IS ELIGIBLE TO RECEIVE UP
TO AN
AGGREGATE OF $3.5 MILLION BASED ON ACHIEVEMENT OF CERTAIN
CLINICAL MILESTONES
* SURFACE ONCOLOGY INC - VACCINEX IS ELIGIBLE TO RECEIVE UP
TO
$11.5 MILLION BASED ON ACHIEVEMENT OF CERTAIN REGULATORY
MILESTONES PER LICENSED PRODUCT
Source text (https://bit.ly/3vQqlEf)
Further company coverage: SURF.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Surface Oncology
See all newsBrief: Surface Oncology Says Anticipates Will Have Net Cash Of $20 Million To $25 Million At The Closing Of The Proposed Mergers
Surface Oncology Inc reports results for the quarter ended in June - Earnings Summary
Brief: Surface Oncology, Inc. Q2 Net Income USD -28.2 Mln
Surface Oncology Inc expected to post a loss of 34 cents a share - Earnings Preview
Brief: ADAR1 Partners Reports 5.24% Passive Stake In Surface Oncology Inc As Of July 10 - SEC Filing